TriSalus Life Sciences to Become Publicly Traded via Merger with MedTech Acquisition Corporation

Adaptimmune Therapeutics And TCR² Therapeutics To Merge (All-Stock)

March 6, 2023

Healthcare Services

Adaptimmune Therapeutics plc and TCR² Therapeutics Inc announced they have entered into a definitive agreement to merge in an all-stock transaction, combining to form a preeminent cell therapy company focused on solid tumors. The merged company will leverage complementary engineered T-cell technology platforms (SPEAR and TRuC) and is expected to extend its cash runway into 2026 following closing.

Mercalis (formerly TrialCard) Acquires Triangle Insights Group

April 12, 2022

Healthcare Services

Mercalis (formerly TrialCard) acquired Triangle Insights Group, a Durham-based life sciences strategy consulting firm, to expand its commercialization capabilities. The transaction is an add-on to the Mercalis platform (which is backed by Odyssey Investment Partners) and will retain all TIG partners and employees as Mercalis integrates strategic insights, pricing and market access expertise into its full-service commercialization offering.

Comera Life Sciences to Go Public via Business Combination with OTR Acquisition Corp.

January 31, 2022

Healthcare Services

Comera Life Sciences entered into a business combination agreement with publicly traded special purpose acquisition company OTR Acquisition Corp. to become a publicly listed company. The transaction is expected to provide Comera with access to public equity markets and approximately $107 million in gross proceeds (subject to redemptions).

SAB Biotherapeutics to Go Public via Merger with Big Cypress Acquisition Corp.

October 20, 2021

Biotechnology

SAB Biotherapeutics entered into a definitive business combination/merger agreement with Big Cypress Acquisition Corp. (a SPAC), with the combined company to operate as SAB Biotherapeutics and be listed on Nasdaq. Big Cypress stockholders approved the deal, and the transaction was expected to close on or about October 22, 2021, subject to customary conditions.

Candid Therapeutics to Merge With Rallybio (Creating Nasdaq-listed Candid Therapeutics)

March 5, 2026

Biotechnology

Clinical-stage biotechnology company Candid Therapeutics signed a merger agreement with Rallybio Corporation to create a combined company focused on developing T cell engager therapies for autoimmune diseases. The transaction is expected to close in mid-2026, pending customary approvals and conditions, and Candid also secured an oversubscribed private financing of more than $505 million led by healthcare institutional investors.

Media Tech SPAC plc to Acquire Drylab A/S

March 28, 2022

Cloud & SaaS

Media Tech SPAC plc (MTS) entered into a definitive agreement to acquire 100% of the share capital of Drylab A/S, a Scandinavia-based film and TV production SaaS platform. The acquisition is expected to complete in the coming weeks, after which the combined businesses will be renamed Drylab Media Tech plc.